<DOC>
	<DOCNO>NCT01444092</DOCNO>
	<brief_summary>A Safety Study use Entocort EC child mild moderate Crohn 's Disease</brief_summary>
	<brief_title>Safety Study Entocort Children With Crohn 's Disease</brief_title>
	<detailed_description>A Multicenter , Open label , Non-comparative Study Evaluate Safety Entocort EC Treatment Crohn 's Disease Paediatric Subjects Aged 5 17 Years , Inclusive</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>All male female subject must age 5 17 , inclusive , must reach 18th birthday estimate final office visit . Subject must diagnose active Crohn 's disease ileum and/or ascend colon confirm endoscopic and/or radiographic evidence , and/or evidence mucosal erosion and/or histology . Subjects mild moderate Crohn 's disease . All subject must stool analysis negative Clostridium difficile toxin , Yersinia enterolytica , Campylobacter jejuni , Salmonella , Shigella , within 30 day prior visit 1 . All subject must laboratory assessment within 7 day prior visit 1 . All subject must weigh &gt; = 15 kg time enrollment Subjects previous intestinal resection proximal include ascend colon Subjects evidence severe active Crohn 's disease and/or , stricturing prestenotic dilatation , clinical evidence obstruction , perirectal abscess , perirectal disease active draining fistula , perforation , septic complication Subjects negative stool analysis , within 30 day prior visit 1 Subjects screened/or enrol study previously within last 30 day Subjects morning cortisol level &lt; 150 nmol/l ( 5.4 ug/dl ) DHEAS normal range age gender</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>